


Second Announcement

Targeted Protein Degradation 5
21st - 22nd October 2026

The Fielder Centre, Hatfield

Registration open!

Abstract submission open!



Abstract
Submission



#ProtDeg26

Second Announcement

Confirmed Speakers

Alessio Ciulli, University of Dundee

Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact

Joshua Clark, TRIMTECH Therapeutics

Leveraging the Clustering-Based Activation Mechanism of TRIM21 to Degrade Pathological Protein Aggregates

Mattia Cocco, AstraZeneca

Degrader Antibody Conjugates: the good, the bad and the case studies

Peter Cossar, University of Dundee

Hijacking Protein Complexes: Induced Chemical Ubiquitination of 14-3-3 Complexes Enables Targeting of Non-Ligandable Proteins

Lindsay Evans, ICR

Unhooking the Hook: Optimisation of the Aurora A Targeting PROTAC JB170 to CCT400028, and in vitro Degradation Chemical Probe

Krista Goodman, Larkspur Bio

Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma

Benoit Gourdet, Sygnature Discovery

Induced Proximity Strategies for Targeted Protein Degradation and Emerging Modalities

Lyn Jones, Dana-Farber Cancer Institute

Rewriting E3 Ligase Function: The Discovery and Development of Cereblon-Neofunctionalizing Molecular Glues

Suzanne O'Connor, University of Dundee

Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation

Kristin Riching, Promega

Understanding How Cell Context and Intrinsic Factors Contribute to PROTAC Activity

Markus Schade, AstraZeneca

AZD9750 and the new Rule-of-oral-PROTACs

Dom Lukauskis, Ternary Therapeutics

A computational platform for the design of any molecular glue

Confirmed Exhibitors / Sponsors

